Table 3.

Difference in concentrations of plasma biomarkers between study groups (pravastatin versus placebo) over the 3-year study period compared with the baseline

Variable (Δ)PravastatinPlaceboP Value
Asymmetric dimethylarginine, µM0.07±0.090.03±0.100.09
Arginine, µM−9.49±27.36−9.73±31.150.97
Citrulline, µM0.28±6.441.39±7.740.48
Cysteine, µM2.91±30.2214.47±30.250.08
Homocysteine, µM0.57±8.202.83±6.300.17
Methionine, µM6.58±9.443.19±13.310.18
S-adenosyl methionine, nM−2.55±37.76−0.78±31.650.84
S-adenosyl homocysteine, nM−4.41±6.09−4.03±6.600.74
9-HODE, ng/ml−2.05±6.251.01±3.30.02
13-HODE, ng/ml−1.82±6.843.32±6.820.004
8-HETE, ng/ml−0.02±0.090.04±0.170.14
11-HETE, ng/ml−0.13±0.18−0.01±0.380.12
12-HETE, ng/ml−0.79±2.942.15±11.500.18
15-HETE, ng/ml−0.28±0.550.18±1.040.04
20-HETE, ng/ml−0.05±0.170.00±0.110.15
15-HEPE, ng/ml−0.03±0.05−0.01±0.030.15
  • Data are presented as the mean±SD. HODE, hydroxyoctadecadienoic acid; HETE, hydroxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid.